How much revenue did Ergomed generate this year?
Ergomed has achieved a revenue of 183.93 M GBP this year.
Ergomed Revenue 2024
Ergomed Revenue
183.93 M GBP
Ticker
ERGO.L
ISIN
GB00BN7ZCY67
WKN
A117XM
In 2024, Ergomed's sales reached 183.93 M GBP, a 11.13% difference from the 165.51 M GBP sales recorded in the previous year.
The Ergomed Revenue history
| YEAR | REVENUE (undefined GBP) | GROSS MARGIN (%) |
|---|---|---|
| 2030e | 269.32 | 21,96 |
| 2029e | 253.92 | 23,29 |
| 2028e | 238.66 | 24,78 |
| 2027e | 235.55 | 25,11 |
| 2026e | 220.14 | 26,87 |
| 2025e | 199.37 | 29,67 |
| 2024e | 183.93 | 32,16 |
| 2023e | 165.51 | 35,74 |
| 2022 | 145.26 | 40,72 |
| 2021 | 118.58 | 40,78 |
| 2020 | 86.39 | 45,90 |
| 2019 | 68.26 | 43,26 |
| 2018 | 54.11 | 35,58 |
| 2017 | 47.62 | 36,99 |
| 2016 | 39.23 | 30,57 |
| 2015 | 30.18 | 27,74 |
| 2014 | 21.16 | 27,27 |
| 2013 | 15.15 | 33,00 |
| 2012 | 14.61 | 26,90 |
| 2011 | 12.07 | 32,81 |
Ergomed Revenue, EBIT, Net Income GB00BN7ZCY67 · A117XM
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Ergomed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ergomed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ergomed’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Ergomed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Ergomed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Ergomed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ergomed’s growth potential.
Ergomed Revenue, EBIT and net profit per share
| Date | Ergomed Revenue | Ergomed EBIT | Ergomed Net Income |
|---|---|---|---|
| 2030e | 269.32 M undefined | 46.07 M undefined | 0 undefined |
| 2029e | 253.92 M undefined | 44.32 M undefined | 0 undefined |
| 2028e | 238.66 M undefined | 42.66 M undefined | 0 undefined |
| 2027e | 235.55 M undefined | 46.14 M undefined | 37.57 M undefined |
| 2026e | 220.14 M undefined | 41.79 M undefined | 36.76 M undefined |
| 2025e | 199.37 M undefined | 36.96 M undefined | 29.96 M undefined |
| 2024e | 183.93 M undefined | 31.97 M undefined | 27.18 M undefined |
| 2023e | 165.51 M undefined | 27.85 M undefined | 24.01 M undefined |
| 2022 | 145.26 M undefined | 20.54 M undefined | 14.98 M undefined |
| 2021 | 118.58 M undefined | 19.35 M undefined | 12.67 M undefined |
| 2020 | 86.39 M undefined | 14.39 M undefined | 9.68 M undefined |
| 2019 | 68.26 M undefined | 7.91 M undefined | 5.57 M undefined |
| 2018 | 54.11 M undefined | -1.04 M undefined | -8.98 M undefined |
| 2017 | 47.62 M undefined | -2.75 M undefined | -4.5 M undefined |
| 2016 | 39.23 M undefined | 1.36 M undefined | -70,000 undefined |
| 2015 | 30.18 M undefined | 2.38 M undefined | 1.55 M undefined |
| 2014 | 21.16 M undefined | 1.36 M undefined | 578,000 undefined |
| 2013 | 15.15 M undefined | 1.78 M undefined | 1.55 M undefined |
| 2012 | 14.61 M undefined | 470,000 undefined | 390,000 undefined |
| 2011 | 12.07 M undefined | 620,000 undefined | 540,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 12.07 M GBP | 620,000 GBP | 540,000 GBP |
| 2012 | 14.61 M GBP | 470,000 GBP | 390,000 GBP |
| 2013 | 15.15 M GBP | 1.78 M GBP | 1.55 M GBP |
| 2014 | 21.16 M GBP | 1.36 M GBP | 578,000 GBP |
| 2015 | 30.18 M GBP | 2.38 M GBP | 1.55 M GBP |
| 2016 | 39.23 M GBP | 1.36 M GBP | -70,000 GBP |
| 2017 | 47.62 M GBP | -2.75 M GBP | -4.5 M GBP |
| 2018 | 54.11 M GBP | -1.04 M GBP | -8.98 M GBP |
| 2019 | 68.26 M GBP | 7.91 M GBP | 5.57 M GBP |
| 2020 | 86.39 M GBP | 14.39 M GBP | 9.68 M GBP |
| 2021 | 118.58 M GBP | 19.35 M GBP | 12.67 M GBP |
| 2022 | 145.26 M GBP | 20.54 M GBP | 14.98 M GBP |
| 2023e | 165.51 M GBP | 27.85 M GBP | 24.01 M GBP |
| 2024e | 183.93 M GBP | 31.97 M GBP | 27.18 M GBP |
| 2025e | 199.37 M GBP | 36.96 M GBP | 29.96 M GBP |
| 2026e | 220.14 M GBP | 41.79 M GBP | 36.76 M GBP |
| 2027e | 235.55 M GBP | 46.14 M GBP | 37.57 M GBP |
| 2028e | 238.66 M GBP | 42.66 M GBP | 0 GBP |
| 2029e | 253.92 M GBP | 44.32 M GBP | 0 GBP |
| 2030e | 269.32 M GBP | 46.07 M GBP | 0 GBP |
Ergomed stock margins GB00BN7ZCY67 · A117XM
The Ergomed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ergomed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ergomed.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Ergomed's sales revenue. A higher gross margin percentage indicates that the Ergomed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Ergomed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Ergomed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ergomed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ergomed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ergomed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Ergomed Margin History
| Ergomed Gross margin | Ergomed Profit margin | Ergomed EBIT margin | Ergomed Profit margin |
|---|---|---|---|
| 2030e | 40.72 % | 17.11 % | 0 % |
| 2029e | 40.72 % | 17.45 % | 0 % |
| 2028e | 40.72 % | 17.88 % | 0 % |
| 2027e | 40.72 % | 19.59 % | 15.95 % |
| 2026e | 40.72 % | 18.98 % | 16.7 % |
| 2025e | 40.72 % | 18.54 % | 15.03 % |
| 2024e | 40.72 % | 17.38 % | 14.78 % |
| 2023e | 40.72 % | 16.83 % | 14.51 % |
| 2022 | 40.72 % | 14.14 % | 10.31 % |
| 2021 | 40.78 % | 16.32 % | 10.69 % |
| 2020 | 45.9 % | 16.65 % | 11.21 % |
| 2019 | 43.26 % | 11.59 % | 8.16 % |
| 2018 | 35.58 % | -1.92 % | -16.6 % |
| 2017 | 36.99 % | -5.77 % | -9.46 % |
| 2016 | 30.57 % | 3.47 % | -0.18 % |
| 2015 | 27.74 % | 7.89 % | 5.14 % |
| 2014 | 27.27 % | 6.44 % | 2.73 % |
| 2013 | 33 % | 11.75 % | 10.23 % |
| 2012 | 26.9 % | 3.22 % | 2.67 % |
| 2011 | 32.81 % | 5.14 % | 4.47 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | 32.81 % | 5.14 % | 4.47 % |
| 2012 | 26.9 % | 3.22 % | 2.67 % |
| 2013 | 33 % | 11.75 % | 10.23 % |
| 2014 | 27.27 % | 6.44 % | 2.73 % |
| 2015 | 27.74 % | 7.89 % | 5.14 % |
| 2016 | 30.57 % | 3.47 % | -0.18 % |
| 2017 | 36.99 % | -5.77 % | -9.46 % |
| 2018 | 35.58 % | -1.92 % | -16.6 % |
| 2019 | 43.26 % | 11.59 % | 8.16 % |
| 2020 | 45.9 % | 16.65 % | 11.21 % |
| 2021 | 40.78 % | 16.32 % | 10.69 % |
| 2022 | 40.72 % | 14.14 % | 10.31 % |
| 2023e | 40.72 % | 16.83 % | 14.51 % |
| 2024e | 40.72 % | 17.38 % | 14.78 % |
| 2025e | 40.72 % | 18.54 % | 15.03 % |
| 2026e | 40.72 % | 18.98 % | 16.7 % |
| 2027e | 40.72 % | 19.59 % | 15.95 % |
| 2028e | 40.72 % | 17.88 % | 0 % |
| 2029e | 40.72 % | 17.45 % | 0 % |
| 2030e | 40.72 % | 17.11 % | 0 % |
Ergomed Aktienanalyse
What does Ergomed do?
Ergomed PLC is a company specialized in clinical research, based in the UK since 1997. It specializes in supporting biotech and pharmaceutical companies in conducting clinical phase studies and post-marketing surveillance. Ergomed is listed on the London Stock Exchange and has offices in Europe and the USA. The company was originally founded as Ergomed Clinical Research Limited by physician Miroslav Reljanovic, who recognized the lack of resources for small biotech companies to conduct their own clinical studies. Ergomed offers a range of services tailored to the needs of biotech and pharmaceutical companies, including clinical research services, medical information and pharmacovigilance services, and regulatory affairs. It also provides venture capital investments for selected biotech companies. Ergomed offers comprehensive clinical research services, including study planning, trial management, and study monitoring. It also has expertise in data management and statistics to ensure accurate results. The company provides medical information to inform patients and healthcare professionals and offers support for drug monitoring during and after approval. Ergomed also supports companies in submitting regulatory applications and addressing regulatory questions. It has extensive experience working with national, European, and global regulatory authorities to ensure drug approval and compliance. Ergomed does not offer its own products but provides services to biotech and pharmaceutical companies. It collaborates with various companies to conduct clinical trials and develop drugs. In conclusion, Ergomed is a specialized company in clinical research that offers a wide range of services to biotech and pharmaceutical companies. It specializes in supporting them in conducting clinical phase studies and post-marketing surveillance. Ergomed has extensive experience working with regulatory authorities at national, European, and global levels to ensure drug approval and compliance. Ergomed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Ergomed's Sales Figures
The sales figures of Ergomed originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Ergomed’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Ergomed's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Ergomed’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Ergomed stock
How much was the turnover of the company Ergomed compared to the previous year?
The revenue of Ergomed has increased by 11.13% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Ergomed?
The revenue of Ergomed is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Ergomed measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Ergomed so important for investors?
The revenue of Ergomed is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Ergomed pay?
Over the past 12 months, Ergomed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ergomed is expected to pay a dividend of 0 GBP.
What is the dividend yield of Ergomed?
The current dividend yield of Ergomed is .
When does Ergomed pay dividends?
Ergomed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Ergomed?
Ergomed paid dividends every year for the past 0 years.
What is the dividend of Ergomed?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Ergomed located?
Ergomed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Ergomed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Ergomed from 9/13/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
When did Ergomed pay the last dividend?
The last dividend was paid out on 9/13/2024.
What was the dividend of Ergomed in the year 2023?
In the year 2023, Ergomed distributed 0 GBP as dividends.
In which currency does Ergomed pay out the dividend?
The dividends of Ergomed are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Ergomed stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Ergomed
Our stock analysis for Ergomed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ergomed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
